Patterns of nicotinic receptor antagonism II: cardiovascular effects in rats.

[1]  M. Javors,et al.  Pharmacologic Characterization of a Nicotine-Discriminative Stimulus in Rhesus Monkeys , 2012, Journal of Pharmacology and Experimental Therapeutics.

[2]  E. Jutkiewicz,et al.  Patterns of Nicotinic Receptor Antagonism: Nicotine Discrimination Studies , 2011, Journal of Pharmacology and Experimental Therapeutics.

[3]  C. Furberg,et al.  Risk of serious adverse cardiovascular events associated with varenicline: a systematic review and meta-analysis , 2011, Canadian Medical Association Journal.

[4]  N. Chaudhri,et al.  Self-administered and yoked nicotine produce robust increases in blood pressure and changes in heart rate with modest effects of behavioral contingency in rats , 2011, Pharmacology Biochemistry and Behavior.

[5]  Jill M Williams,et al.  Varenicline for tobacco dependence: panacea or plight? , 2011, Expert opinion on pharmacotherapy.

[6]  L. McMahon,et al.  The effects of nicotine, varenicline, and cytisine on schedule-controlled responding in mice: differences in α4β2 nicotinic receptor activation. , 2011, European journal of pharmacology.

[7]  Carly LaCroix,et al.  Cytisine induces autonomic cardiovascular responses via activations of different nicotinic receptors , 2010, Autonomic Neuroscience.

[8]  H. Navarro,et al.  Synthesis, nicotinic acetylcholine receptor binding, and antinociceptive properties of 3'-(substituted phenyl)epibatidine analogues. Nicotinic partial agonists. , 2010, Journal of natural products.

[9]  Jessica L. Freeling,et al.  Specific subtypes of nicotinic cholinergic receptors involved in sympathetic and parasympathetic cardiovascular responses , 2009, Neuroscience Letters.

[10]  S. Goldberg,et al.  Baseline Expression of α4β2* Nicotinic Acetylcholine Receptors Predicts Motivation to Self-administer Nicotine , 2009, Biological Psychiatry.

[11]  F. Carroll,et al.  Effects of the nicotinic receptor partial agonists varenicline and cytisine on the discriminative stimulus effects of nicotine in rats , 2009, Pharmacology Biochemistry and Behavior.

[12]  Y. Goshima,et al.  DOPA cyclohexyl ester, a DOPA antagonist, blocks the depressor responses elicited by microinjections of nicotine into the nucleus tractus solitarii of rats , 2008, Neuroscience Letters.

[13]  A. Delaunois,et al.  Repeated assessment of cardiovascular and respiratory functions using combined telemetry and whole-body plethysmography in the rat. , 2008, Journal of pharmacological and toxicological methods.

[14]  M. Sofuoglu,et al.  Self-Administration of Intravenous Nicotine in Male and Female Cigarette Smokers , 2008, Neuropsychopharmacology.

[15]  Hiroyasu Ito,et al.  Changes in neuronal protein expression in LP-BM5-infected mice , 2007, Neuroscience Letters.

[16]  E. Donny,et al.  Reinforcement enhancing effect of nicotine and its attenuation by nicotinic antagonists in rats , 2007, Psychopharmacology.

[17]  W. Dewé,et al.  Comparison of two methods (left carotid artery and abdominal aorta) for surgical implantation of radiotelemetry devices in CD-1 mice , 2007, Laboratory animals.

[18]  R. J. Mather,et al.  Pharmacological profile of the α4β2 nicotinic acetylcholine receptor partial agonist varenicline, an effective smoking cessation aid , 2007, Neuropharmacology.

[19]  P. Szekeres,et al.  Ligands selective for α4β2 but not α3β4 or α7 nicotinic receptors generalise to the nicotine discriminative stimulus in the rat , 2006, Psychopharmacology.

[20]  K. Kellar,et al.  Heterogeneity of Nicotinic Cholinergic Receptors in Rat Superior Cervical and Nodose Ganglia , 2006, Molecular Pharmacology.

[21]  F. Ivy Carroll,et al.  Varenicline Is a Partial Agonist at α4β2 and a Full Agonist at α7 Neuronal Nicotinic Receptors , 2006, Molecular Pharmacology.

[22]  M. Filip,et al.  Evaluation of the role of nicotinic acetylcholine receptor subtypes and cannabinoid system in the discriminative stimulus effects of nicotine in rats. , 2006, European journal of pharmacology.

[23]  C. Gotti,et al.  Brain neuronal nicotinic receptors as new targets for drug discovery. , 2006, Current pharmaceutical design.

[24]  T. Gnecchi-Ruscone,et al.  Alpha7-nicotinic acetylcholine receptor subunit is not required for parasympathetic control of the heart in the mouse. , 2005, Physiological genomics.

[25]  Brian T. O’Neill,et al.  Varenicline: An α4β2 Nicotinic Receptor Partial Agonist for Smoking Cessation , 2005 .

[26]  A. C. Collins,et al.  Subunit composition and pharmacology of two classes of striatal presynaptic nicotinic acetylcholine receptors mediating dopamine release in mice. , 2004, Molecular pharmacology.

[27]  P. Insel,et al.  Autonomic Nervous System Pharmacogenomics: A Progress Report , 2004, Pharmacological Reviews.

[28]  C. Gotti,et al.  Nicotinic Acetylcholine Receptor Subtypes in the Rat Sympathetic Ganglion: Pharmacological Characterization, Subcellular Distribution and Effect of Pre‐ and Postganglionic Nerve Crush , 2004, Journal of neuropathology and experimental neurology.

[29]  E. Sher,et al.  Pharmacological Properties of α9α10 Nicotinic Acetylcholine Receptors Revealed by Heterologous Expression of Subunit Chimeras , 2004 .

[30]  Ortrud K. Steinlein,et al.  Characterization of Human α4β2-Nicotinic Acetylcholine Receptors Stably and Heterologously Expressed in Native Nicotinic Receptor-Null SH-EP1 Human Epithelial Cells , 2003 .

[31]  John L. Musachio,et al.  Measuring nicotinic receptors with characteristics of α4β2, α3β2 and α3β4 subtypes in rat tissues by autoradiography , 2002 .

[32]  I. Stolerman,et al.  The role of nicotinic receptor beta-2 subunits in nicotine discrimination and conditioned taste aversion , 2002, Neuropharmacology.

[33]  J. Genzen,et al.  Dorsal root ganglion neurons express multiple nicotinic acetylcholine receptor subtypes. , 2001, Journal of neurophysiology.

[34]  H. Sapru,et al.  Cardiovascular responses to microinjections of nicotine into the caudal ventrolateral medulla of the rat , 2001, Brain Research.

[35]  M. Shoaib,et al.  Antagonism of the discriminative and aversive stimulus properties of nicotine in C57BL/6J mice , 2000, Neuropharmacology.

[36]  J. Rose,et al.  Dissociating nicotine and nonnicotine components of cigarette smoking , 2000, Pharmacology Biochemistry and Behavior.

[37]  A. Beaudet,et al.  Altered baroreflex responses in α7 deficient mice , 2000, Behavioural Brain Research.

[38]  K. Kellar,et al.  Brainstem nicotinic receptor subtypes that influence intragastric and arterial blood pressures. , 2000, The Journal of pharmacology and experimental therapeutics.

[39]  J. McIntosh,et al.  Functional Nicotinic Acetylcholine Receptors That Mediate Ganglionic Transmission in Cardiac Parasympathetic Neurons , 2000, The Journal of Neuroscience.

[40]  R. Mansbach,et al.  Effects of the competitive nicotinic antagonist erysodine on behavior occasioned or maintained by nicotine: comparison with mecamylamine , 2000, Psychopharmacology.

[41]  A. Ferrari,et al.  Sympathectomy inhibits the vasoactive effects of nicotine in conscious rats. , 1999, Cardiovascular research.

[42]  G. Koob,et al.  Blockade of Nicotine Self-Administration with Nicotinic Antagonists in Rats , 1999, Pharmacology Biochemistry and Behavior.

[43]  J. Lake,et al.  Nicotine Abstinence Syndrome Precipitated by Central But Not Peripheral Hexamethonium , 1997, Pharmacology Biochemistry and Behavior.

[44]  I. Stolerman,et al.  Discriminative stimulus properties of the nicotinic agonist cytisine , 1997, Psychopharmacology.

[45]  I. Stolerman,et al.  Selective antagonism of behavioural effects of nicotine by dihydro-β-erythroidine in rats , 1997, Psychopharmacology.

[46]  David John Adams,et al.  Heterogeneity of Nicotinic Receptor Class and Subunit mRNA Expression among Individual Parasympathetic Neurons from Rat Intracardiac Ganglia , 1997, The Journal of Neuroscience.

[47]  D. Bertrand,et al.  Human α4β2 Neuronal Nicotinic Acetylcholine Receptor in HEK 293 Cells: A Patch-Clamp Study , 1996, The Journal of Neuroscience.

[48]  E. London,et al.  Subjective and cardiovascular effects of intravenous nicotine in smokers and non-smokers , 1996, Psychopharmacology.

[49]  C. Luetje,et al.  Multiple Determinants of Dihydro‐β‐Erythroidine Sensitivity on Rat Neuronal Nicotinic Receptor α Subunits , 1996 .

[50]  C. Luetje,et al.  Determinants of Competitive Antagonist Sensitivity on Neuronal Nicotinic Receptor β Subunits , 1996, The Journal of Neuroscience.

[51]  A. C. Collins,et al.  Nicotinic agonists differ in activation and desensitization of 86Rb+ efflux from mouse thalamic synaptosomes. , 1996, The Journal of pharmacology and experimental therapeutics.

[52]  J. Diana,et al.  Cardiovascular responses to cigarette smoke exposure in restrained conscious rats. , 1995, The Journal of pharmacology and experimental therapeutics.

[53]  T. Yaksh,et al.  Augmented responses to intrathecal nicotinic agonists in spontaneous hypertension. , 1994, Hypertension.

[54]  W. Corrigall,et al.  Self-administered nicotine activates the mesolimbic dopamine system through the ventral tegmental area , 1994, Brain Research.

[55]  D. Robertson,et al.  Effects of nicotine on brain stem mechanisms of cardiovascular control. , 1993, The Journal of pharmacology and experimental therapeutics.

[56]  R. Freedman,et al.  Characterization of [3H]cytisine binding to human brain membrane preparations , 1993, Brain Research.

[57]  V. Savci,et al.  Effects of Intracerebroventricular Injected Choline on Cardiovascular Functions and Sympathoadrenal Activity , 1991, Journal of cardiovascular pharmacology.

[58]  B. Testa,et al.  Behavioural and pharmacokinetic studies on nicotine, cytisine and lobeline , 1990, Neuropharmacology.

[59]  R. Hook,et al.  The comparative binding characteristics of nicotinic ligands and their pharmacology , 1988, Pharmacology Biochemistry and Behavior.

[60]  J. Henningfield,et al.  Abuse liability and pharmacodynamic characteristics of intravenous and inhaled nicotine. , 1985, The Journal of pharmacology and experimental therapeutics.

[61]  J. Pratt,et al.  Nicotine cue in rats analysed with drugs acting on cholinergic and 5-hydroxytryptamine mechanisms , 1983, Neuropharmacology.

[62]  Y. Misu,et al.  Changes in arterial blood pressure after microinjections of nicotine into the dorsal area of the medulla oblongata of the rat , 1981, Neuropharmacology.

[63]  A. Horsch,et al.  Evaluation of smoking-induced effects on sympathetic, hemodynamic and metabolic variables with respect to plasma nicotine and COHb levels. , 1979, Atherosclerosis.

[64]  M. Sackner,et al.  Hemodynamic effects of smoking cigarettes of high and low nicotine content. , 1978, Chest.

[65]  L. J. Roth,et al.  Entry and distribution of hexamethonium in the central nervous system. , 1971, Biochemical pharmacology.

[66]  R. Nadeau,et al.  Effects of nicotine on heart rate studied by direct perfusion of sinus code. , 1967, The American journal of physiology.

[67]  Janice W. Smith,et al.  Recognising nicotine: the neurobiological basis of nicotine discrimination. , 2009, Handbook of experimental pharmacology.

[68]  W. Kübler,et al.  Nicotine and sympathetic neurotransmission , 2004, Cardiovascular Drugs and Therapy.

[69]  D. Robertson,et al.  Smoking and mechanisms of cardiovascular control. , 1988, American heart journal.

[70]  A. Horsch,et al.  Acute cardiovascular reactions after cigarette smoking. , 1980, Atherosclerosis.